CCM
KDNY

CAAS Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

CAAS Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-60,717
Closed -$775K – 1122
2021
Q3 		$775K Sell
60,717
-285,716
-82% -$3.76M 0.02% 542
2021
Q2 		$4.89M Buy
+346,433
New +$5.54M 0.08% 243

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAAS Capital Management's KDNY Position: Q4 2021 in Review

CAAS Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2021, closing a stake of 60,717 shares — an estimated $775K sold.

CAAS Capital Management first reported a position in KDNY in Q2 2021 and held it in 2 quarters. The position peaked at $4.89M in Q2 2021. 103 funds tracked by Wall St. Rank hold KDNY as of Q4 2021.

  • CAAS Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 60,717 Chinook Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $775K.
  • CAAS Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • CAAS Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $4.89M in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.